U.S. Markets close in 3 hrs 54 mins
Stocks to Watch

Sempra outbids Buffett for Oncor, Fiat Chrysler soars, Nike gets downgraded

Shire plc (SHPG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
140.69-4.86 (-3.34%)
As of 12:05PM EDT. Market open.
People also watch
ALXNJAZZBMRNREGNBAX
Full screen
Previous Close145.55
Open142.94
Bid140.14 x 200
Ask140.27 x 200
Day's Range139.38 - 143.35
52 Week Range139.38 - 209.22
Volume2,275,626
Avg. Volume1,333,455
Market Cap42.57B
Beta1.65
PE Ratio (TTM)144.30
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.92 (0.63%)
Ex-Dividend Date2017-03-08
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com42 minutes ago

    Shire: There Goes the CFO!

    It's never good news for a stock when a chief financial officer suddenly departs--and that's certainly the case for Shire (SHPG) today, which announced that CFO Jeff Poulton would be leaving the company to join a startup. A CFO's departure is often taken as a sign that deeper issues could emerge at a company, and that's probably what's happening at Shire. The stock, after all, has dropped 14% so far this year, as investors fretted about the impact of weakening generic sales following Teva Pharmaceutical Industries' (TEVA) earnings on specialty pharmaceutical stocks of all stripes.

  • Shire Files Marketing Application for Lifitegrast in Europe
    Zacks5 days ago

    Shire Files Marketing Application for Lifitegrast in Europe

    Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.

  • American City Business Journals6 days ago

    Shire applies for European approval of potential blockbuster eye drop

    One of the state’s biggest biotech employers, Shire plc, has applied for European approval for its potential blockbuster eye drop to treat dry eye disease, sold by the name of Xiidra in the U.S. The drug, a twice-a-day eye drop that goes by the generic name of lifitegrast, was approved in the U.S. in August 2016. It’s touted as the “first and only” drug in the world to treat the signs and symptoms of dry eye disease, and competes head-to-head with Restasis, a similarly-priced drug sold by Allergan plc (AGN) that’s approved to increase tear production due to inflammation.